Korean J Med 2023;98:84-87. <ext-link xlink:href="https://doi.org/10.3904/kjm.2023.98.2.84" ext-link-type="uri">https://doi.org/10.3904/kjm.2023.98.2.84</ext-link> 다음과 같이 본문 내 오류가 있어 수정합니다. 수정 전 <xref rid="t1-kjm-99-4-224" ref-type="table"/> 수정 후 <xref rid="t2-kjm-99-4-224" ref-type="table"/> </sec> <sec> <title>수정 전

KJM

The Korean Journal of Medicine

Korean J Med

1738-9364 2289-0769

The Korean Journal of Medicine

10.3904/kjm.2023.98.2.84.e1

kjm-99-4-224

Erratum

비침습적 간섬유화 검사의 적용

Non-Invasive Evaluation of Liver Fibrosis

Heo

Nae-Yun

허

내윤

Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea 인제대학교 의과대학 인제대학교 해운대백병원 내과

1 8 2024

99 4 224 225

2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Korean J Med 2023;98:84-87. <ext-link xlink:href="https://doi.org/10.3904/kjm.2023.98.2.84" ext-link-type="uri">https://doi.org/10.3904/kjm.2023.98.2.84</ext-link> 다음과 같이 본문 내 오류가 있어 수정합니다. 수정 전 <xref rid="t1-kjm-99-4-224" ref-type="table"/> 수정 후 <xref rid="t2-kjm-99-4-224" ref-type="table"/> </sec> <sec> <title>수정 전

1. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.

2. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726-736.

3. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 2015;61:292-302.

4. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325.

5. Kim BK, Kim DY, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int 2010;30:546-553.

6. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7: 1104-1112.

7. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713.

8. Yu JH, Lee HA, Kim SU. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future. Clin Mol Hepatol 2023;29 Suppl:S136-S149.

9. Kim BK, Tamaki N, Imajo K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. J Hepatol 2022;77:1482-1490.

10. Kang SH, Lee HW, Yoo JJ, et al. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401.

11. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2022;28:276-331.

수정 후

1. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.

4. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325.

6. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7:1104-1112.

7. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713.

8. Yu JH, Lee HA, Kim SU. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future. Clin Mol Hepatol 2023;29 Suppl:S136-S149.

9. Kim BK, Tamaki N, Imajo K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. J Hepatol 2022;77:1482-1490.

10. Kang SH, Lee HW, Yoo JJ, et al. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401.

11. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2022;28:276-331.

12. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.

13. Li Y, Huang YS, Wang ZZ, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther 2016;43:458-469.

14. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156:1717-1730.

15. Nguyen-Khac E, Thiele M, Voican C, et al. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol 2018;3:614-625.

Tables

Table 1.

Diagnostic performance of transient elastography in chronic liver diseases

Etiology	Liver fibrosis
	≥ F2		≥ F3		F4
	Cut-off (kPa)	AUROC	Cut-off (kPa)	AUROC	Cut-off (kPa)	AUROC
HCV [8]	7.1	0.83	9.5	0.90	12.5	0.95
HBV [9]	7.2	0.88	9.4	0.91	12.2	0.93
NAFLD [10]	8.2	0.77	9.7	0.80	13.6	0.89
Alcohol [11]	9.0	0.86	12.1	0.90	18.6	0.91

Table 1.

Diagnostic performance of transient elastography in chronic liver diseases

Etiology	Liver fibrosis
	≥ F2		≥ F3		F4
	Cut-off (kPa)	AUROC	Cut-off (kPa)	AUROC	Cut-off (kPa)	AUROC
HCV [12]	7.1	0.83	9.5	0.90	12.5	0.95
HBV [13]	7.2	0.88	9.4	0.91	12.2	0.93
NAFLD [14]	8.2	0.77	9.7	0.80	13.6	0.89
Alcohol [15]	9.0	0.86	12.1	0.90	18.6	0.91